Ongoing Clinical Trials for Large Cell Lung Cancer Stage 0
There are currently 2 ongoing clinical trials investigating new approaches to detecting and treating large cell lung cancer at its earliest stage. These studies are taking place in Germany, Hungary, and Czechia, testing both new treatment combinations and innovative diagnostic methods to improve patient outcomes.
Clinical trial locations
- Czechia
- Germany
- Hungary
Study on Atezolizumab, Carboplatin, and Etoposide for Adults with Advanced Large-Cell Neuroendocrine Lung Cancer
This trial, being conducted in Germany, is investigating a combination treatment approach for large-cell neuroendocrine carcinoma of the lung, a serious form of cancer where abnormal cells grow rapidly in lung tissue. The study combines an immune system-boosting medication called Atezolizumab with standard chemotherapy drugs Carboplatin (or Cisplatin) and Etoposide, all given directly into the bloodstream through a vein.
Main inclusion criteria: To participate, you must be at least 18 years old and have a confirmed diagnosis of locally advanced or metastatic large-cell neuroendocrine carcinoma that cannot be cured with surgery. If your cancer contains mixed cell types, at least 50% must be large-cell neuroendocrine type. You should not have received previous systemic cancer treatment, although if you had curative treatment that ended at least 6 months ago and the cancer has returned, you may still qualify. You must be able to perform daily activities reasonably well, measured on a scale where 0 means fully active and 2 means you’re up and about more than half the day. Your organs must be functioning adequately, with specific requirements for liver enzymes, bilirubin, kidney function, and blood cell counts.
Main exclusion criteria: You cannot participate if you’ve received other cancer treatments within the last 4 weeks, have severe allergies to the study drugs, have active infections requiring treatment, are pregnant or breastfeeding, or have participated in another clinical trial recently. People with other serious medical conditions, a history of another cancer type (unless in remission for at least 5 years), untreated brain metastases, unstable autoimmune diseases, or recent drug or alcohol abuse are also excluded.
Study focus: The main goal is to evaluate how well this treatment combination works in improving survival rates for patients with this aggressive form of lung cancer. Researchers will monitor how the cancer responds to treatment, including changes in tumor size and how long it takes for the cancer to start growing again. They will also carefully track any side effects participants experience to better understand the safety profile of combining immunotherapy with chemotherapy.
Investigational drugs: Atezolizumab is an immunotherapy that helps your immune system recognize and attack cancer cells by blocking a protein that allows cancer to hide. The platinum-based drugs (Carboplatin or Cisplatin) and Etoposide are chemotherapy medications that work by damaging the DNA of cancer cells, preventing them from growing and dividing.
Study on the Accuracy of OWL-EVO1 Test for Diagnosing Lung Cancer in Patients Eligible for Screening or with Suspicious CT Findings
This diagnostic study, taking place in Hungary and Czechia, is testing an innovative new approach to detecting lung cancer using breath analysis. The OWL-EVO1 Breath Biopsy test aims to help distinguish between people who have lung cancer and those who don’t, offering a potentially non-invasive way to diagnose the disease more accurately and earlier.
Main inclusion criteria: Participants must be between 45 and 85 years old and able to understand and consent to the study. Your Body Mass Index (a measure of weight relative to height) must be between 16 and less than 40. Importantly, you must have had a CT scan of your chest area within the last 6 months.
Main exclusion criteria: You cannot participate if you’re not eligible for lung cancer screening based on low-dose CT scans, if you don’t have any suspicious findings on your CT scan that might suggest lung cancer, or if lung cancer is not being considered as a possible diagnosis for your symptoms.
Study focus: The primary purpose of this study is to determine how accurately the OWL-EVO1 test can identify lung cancer in people undergoing screening or those with suspicious CT scan findings. The test involves administering a special solution through an IV and then collecting breath samples at various times. Researchers will analyze these samples to look for specific markers that may indicate the presence of cancer. The study will also assess the safety and tolerability of the test.
Investigational diagnostic tool: OWL-EVO1 is a diagnostic test that analyzes breath samples to detect specific markers that may indicate lung cancer. It works by identifying volatile organic compounds in the breath, which can signal the presence of cancer. This non-invasive approach could potentially make lung cancer diagnosis easier and more comfortable for patients compared to traditional biopsy methods.
Summary
The two ongoing clinical trials for large cell lung cancer stage 0 represent different but complementary approaches to fighting this disease. One trial focuses on improving treatment outcomes by combining immunotherapy with chemotherapy, while the other aims to enhance early detection through innovative breath-based diagnostics. The trials are distributed across Central Europe, with Germany hosting the treatment study and Hungary and Czechia participating in the diagnostic study. Both studies reflect the current focus in cancer research on improving both detection methods and treatment effectiveness, with an emphasis on patient-friendly approaches such as the non-invasive breath test. These trials offer hope for better outcomes through earlier diagnosis and more effective treatment combinations.
